CG Oncology, Inc.
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -53.36% | 39.38% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -53.36% | 39.38% | |||
| Cost of Revenue | 41.37% | 12.11% | |||
| Gross Profit | -48.53% | -10.47% | |||
| SG&A Expenses | 15.48% | -22.89% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 32.24% | -3.36% | |||
| Operating Income | -36.32% | 4.75% | |||
| Income Before Tax | -45.74% | 5.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -45.74% | 5.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -45.74% | 5.70% | |||
| EBIT | -36.32% | 4.75% | |||
| EBITDA | -36.98% | 5.64% | |||
| EPS Basic | -38.04% | 9.62% | |||
| Normalized Basic EPS | -38.05% | 9.61% | |||
| EPS Diluted | -38.04% | 9.62% | |||
| Normalized Diluted EPS | -38.05% | 9.61% | |||
| Average Basic Shares Outstanding | 5.56% | 4.34% | |||
| Average Diluted Shares Outstanding | 5.56% | 4.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||